| ID | 10012 |
| Vaccine Name | SARS-CoV-2 Vaccine (VeroCell) |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Inactivated |
| Vaccine Status | Approved |
| Manufacturer | Sinopharm, Beijing Institute of Biological Products |
| Year of Manufacturing | 2020 |
| Manufacturing Country | China |
| Age | NA |
| Dosage | 2 doses 21 days apart |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | NA |
| Description | NA |
| Approving Organisation | WHO |
| Collaborating Organisation | NA |
| Other Countries | NA |
| Trade Name | NA |
| PMID | 33816047 |
| Clinical Trial ID | NA |
| Reference Link | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ |
| Additional Links | https://cdn.who.int/media/docs/default-source/immunization/covid-19/16-june-22080-sinopharm-vaccine-explainer-update.pdf?sfvrsn=ad833095_1&download=true
|